SLC-391

SLC-391 is a potent and specific AXL inhibitor (IC₅₀ for AXL is 9.6 nM, while IC₅₀ values ​​for TYRO3 and MER are 42.3 nM and 63.5 nM, respectively). SLC-391 also exhibits good selectivity for TAM kinases compared to other tyrosine kinases^[1].
SLC-391 (0-1 μM; 0-72 h) inhibits SARS-CoV-2 infection of Vero E6 cells in a dose-dependent manner^[1].
SLC-391 (0-1.5 μM; 58 h) dose-dependently blocks the binding of SARS-CoV-2 spike protein to ACE2^[1].
SLC-391 (0-10 μM, 4 days) protects RPMI2650 cells from cytopathic effects induced by human influenza virus, with an EC₅₀ of 0.14 μM, a TC₅₀ >10 μM, and a TI greater than 71.4^[1].
SLC-391 (0.003-10 μM; 4 days) reduces human influenza virus yields in RPMI2650 cells in a concentration-dependent manner in vitro, with reductions of 952.9-fold, 74.9-fold, and 34.8-fold at concentrations of 10 μM, 0.4 μM, and 0.003 μM, respectively^[1].
SLC-391 inhibits Gas6-induced AXL-dependent Akt phosphorylation in human non-small cell lung cancer A549 cells with an IC₅₀ of 0.29 μM^[1].
SLC-391 inhibits the proliferation of AXL-expressing 4T1 cells (IC₅₀ 1.05 μM) and K562 cells (IC₅₀ 3.45 μM)^[1].
SLC-391 (1 μM) completely inhibits the anchorage-independent proliferation of human non-small cell lung cancer A549 cells^[1].
SLC-391 (0.2 μM) inhibits the invasive ability of human non-small cell lung cancer A549 cells by approximately 75%^[1].
SLC-391 increases the number of natural killer cells, elevates the M1/M2 macrophage polarization ratio, subsequently increases the CD8+ T cell/regulatory T cell ratio, and reduces the number of immunosuppressive myeloid cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.